Mon. Apr 19th, 2021

This domain is for sale!

This domain is for sale!

Global Urinary Tract Infection Treatment Industry

17 min read


Global Urinary Tract Infection Treatment Market to Reach US$11. 3 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for Urinary Tract Infection Treatment estimated at US$8.

New York, Dec. 22, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Urinary Tract Infection Treatment Industry” – https://www.reportlinker.com/p05960378/?utm_source=GNW
9 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027.Quinolones, one of the segments analyzed in the report, is projected to grow at a 3.4% CAGR to reach US$4.5 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Aminoglycosides segment is readjusted to a revised 3.7% CAGR for the next 7-year period. This segment currently accounts for a 17% share of the global Urinary Tract Infection Treatment market.

The U.S. Accounts for Over 28.9% of Global Market Size in 2020, While China is Forecast to Grow at a 5.8% CAGR for the Period of 2020-2027

The Urinary Tract Infection Treatment market in the U.S. is estimated at US$2.6 Billion in the year 2020. The country currently accounts for a 28.88% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$1.9 Billion in the year 2027 trailing a CAGR of 5.8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR while Rest of European market (as defined in the study) will reach US$1.9 Billion by the year 2027.

•-lactam Segment Corners a 11.9% Share in 2020

In the global •-lactam segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$802.7 Million in the year 2020 will reach a projected size of US$978.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 3.2% CAGR through the analysis period. We bring years of research experience to this 7th edition of our report. The 188-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Allergan PLC

  • AstraZeneca PLC

  • Bayer AG

  • Johnson & Johnson

  • Lipella Pharmaceuticals Inc.

  • Merck & Co., Inc.

  • MerLion Pharmaceuticals GmbH

  • Mylan Pharmaceutical Pvt. Ltd.

  • Novartis AG

  • Novo Nordisk A/S

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • Urigen Pharmaceuticals, Inc.

Read the full report: https://www.reportlinker.com/p05960378/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Urinary Tract Infection Treatment Competitor Market Share
Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Urinary Tract
Infection Treatment by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Billion for Years 2018 through 2027

Table 2: World Historic Review for Urinary Tract Infection
Treatment by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 3: World 15-Year Perspective for Urinary Tract Infection
Treatment by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2018 & 2027

Table 4: World Current & Future Analysis for Quinolones by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 5: World Historic Review for Quinolones by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 6: World 15-Year Perspective for Quinolones by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Aminoglycosides by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 8: World Historic Review for Aminoglycosides by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 9: World 15-Year Perspective for Aminoglycosides by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 10: World Current & Future Analysis for •-lactam by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 11: World Historic Review for •-lactam by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 12: World 15-Year Perspective for •-lactam by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2018 & 2027

Table 13: World Current & Future Analysis for Azoles by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 14: World Historic Review for Azoles by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 15: World 15-Year Perspective for Azoles by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2018 & 2027

Table 16: World Current & Future Analysis for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 17: World Historic Review for Other Segments by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 18: World 15-Year Perspective for Other Segments by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Urinary Tract Infection Treatment Market Share (in %) by
Company: 2018 & 2027
Market Analytics
Table 19: USA Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 20: USA Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 21: USA 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

CANADA
Table 22: Canada Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 23: Canada Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 24: Canada 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

JAPAN
Table 25: Japan Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 26: Japan Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 27: Japan 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

CHINA
Table 28: China Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 29: China Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 30: China 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

EUROPE
Market Facts & Figures
European Urinary Tract Infection Treatment Market: Competitor
Market Share Scenario (in %) for 2018 & 2027
Market Analytics
Table 31: Europe Current & Future Analysis for Urinary Tract
Infection Treatment by Geographic Region – France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 32: Europe Historic Review for Urinary Tract Infection
Treatment by Geographic Region – France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 33: Europe 15-Year Perspective for Urinary Tract
Infection Treatment by Geographic Region – Percentage Breakdown
of Value Sales for France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets for Years 2012, 2018 & 2027

Table 34: Europe Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 35: Europe Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 36: Europe 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

FRANCE
Table 37: France Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 38: France Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 39: France 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

GERMANY
Table 40: Germany Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 41: Germany Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 42: Germany 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

ITALY
Table 43: Italy Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 44: Italy Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 45: Italy 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

UNITED KINGDOM
Table 46: UK Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 47: UK Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 48: UK 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

SPAIN
Table 49: Spain Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 50: Spain Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 51: Spain 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

RUSSIA
Table 52: Russia Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 53: Russia Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 54: Russia 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

REST OF EUROPE
Table 55: Rest of Europe Current & Future Analysis for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 56: Rest of Europe Historic Review for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 57: Rest of Europe 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

ASIA-PACIFIC
Table 58: Asia-Pacific Current & Future Analysis for Urinary
Tract Infection Treatment by Geographic Region – Australia,
India, South Korea and Rest of Asia-Pacific Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 59: Asia-Pacific Historic Review for Urinary Tract
Infection Treatment by Geographic Region – Australia, India,
South Korea and Rest of Asia-Pacific Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 60: Asia-Pacific 15-Year Perspective for Urinary Tract
Infection Treatment by Geographic Region – Percentage Breakdown
of Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2018 & 2027

Table 61: Asia-Pacific Current & Future Analysis for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 62: Asia-Pacific Historic Review for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 63: Asia-Pacific 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

AUSTRALIA
Table 64: Australia Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 65: Australia Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 66: Australia 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

INDIA
Table 67: India Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 68: India Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 69: India 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

SOUTH KOREA
Table 70: South Korea Current & Future Analysis for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 71: South Korea Historic Review for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 72: South Korea 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

REST OF ASIA-PACIFIC
Table 73: Rest of Asia-Pacific Current & Future Analysis for
Urinary Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 74: Rest of Asia-Pacific Historic Review for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 75: Rest of Asia-Pacific 15-Year Perspective for Urinary
Tract Infection Treatment by Segment – Percentage Breakdown of
Value Sales for Quinolones, Aminoglycosides, •-lactam, Azoles
and Other Segments for the Years 2012, 2018 & 2027

LATIN AMERICA
Table 76: Latin America Current & Future Analysis for Urinary
Tract Infection Treatment by Geographic Region – Argentina,
Brazil, Mexico and Rest of Latin America Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2018 through
2027

Table 77: Latin America Historic Review for Urinary Tract
Infection Treatment by Geographic Region – Argentina, Brazil,
Mexico and Rest of Latin America Markets – Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 78: Latin America 15-Year Perspective for Urinary Tract
Infection Treatment by Geographic Region – Percentage Breakdown
of Value Sales for Argentina, Brazil, Mexico and Rest of Latin
America Markets for Years 2012, 2018 & 2027

Table 79: Latin America Current & Future Analysis for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 80: Latin America Historic Review for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 81: Latin America 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

ARGENTINA
Table 82: Argentina Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 83: Argentina Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 84: Argentina 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

BRAZIL
Table 85: Brazil Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 86: Brazil Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 87: Brazil 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

MEXICO
Table 88: Mexico Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 89: Mexico Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 90: Mexico 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

REST OF LATIN AMERICA
Table 91: Rest of Latin America Current & Future Analysis for
Urinary Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 92: Rest of Latin America Historic Review for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 93: Rest of Latin America 15-Year Perspective for Urinary
Tract Infection Treatment by Segment – Percentage Breakdown of
Value Sales for Quinolones, Aminoglycosides, •-lactam, Azoles
and Other Segments for the Years 2012, 2018 & 2027

MIDDLE EAST
Table 94: Middle East Current & Future Analysis for Urinary
Tract Infection Treatment by Geographic Region – Iran, Israel,
Saudi Arabia, UAE and Rest of Middle East Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2018 through
2027

Table 95: Middle East Historic Review for Urinary Tract
Infection Treatment by Geographic Region – Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 96: Middle East 15-Year Perspective for Urinary Tract
Infection Treatment by Geographic Region – Percentage Breakdown
of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of
Middle East Markets for Years 2012, 2018 & 2027

Table 97: Middle East Current & Future Analysis for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 98: Middle East Historic Review for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 99: Middle East 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

IRAN
Table 100: Iran Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 101: Iran Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 102: Iran 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

ISRAEL
Table 103: Israel Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 104: Israel Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 105: Israel 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

SAUDI ARABIA
Table 106: Saudi Arabia Current & Future Analysis for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 107: Saudi Arabia Historic Review for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments Markets – Independent
Analysis of Annual Sales in US$ Billion for Years 2012 through
2017

Table 108: Saudi Arabia 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

UNITED ARAB EMIRATES
Table 109: UAE Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 110: UAE Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 111: UAE 15-Year Perspective for Urinary Tract Infection
Treatment by Segment – Percentage Breakdown of Value Sales for
Quinolones, Aminoglycosides, •-lactam, Azoles and Other
Segments for the Years 2012, 2018 & 2027

REST OF MIDDLE EAST
Table 112: Rest of Middle East Current & Future Analysis for
Urinary Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments –
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 113: Rest of Middle East Historic Review for Urinary
Tract Infection Treatment by Segment – Quinolones,
Aminoglycosides, •-lactam, Azoles and Other Segments Markets –
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 114: Rest of Middle East 15-Year Perspective for Urinary
Tract Infection Treatment by Segment – Percentage Breakdown of
Value Sales for Quinolones, Aminoglycosides, •-lactam, Azoles
and Other Segments for the Years 2012, 2018 & 2027

AFRICA
Table 115: Africa Current & Future Analysis for Urinary Tract
Infection Treatment by Segment – Quinolones, Aminoglycosides,
•-lactam, Azoles and Other Segments – Independent Analysis of
Annual Sales in US$ Billion for the Years 2018 through 2027

Table 116: Africa Historic Review for Urinary Tract Infection
Treatment by Segment – Quinolones, Aminoglycosides, •-lactam,
Azoles and Other Segments Markets – Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 117: Africa 15-Year Perspective for Urinary Tract
Infection Treatment by Segment – Percentage Breakdown of Value
Sales for Quinolones, Aminoglycosides, •-lactam, Azoles and
Other Segments for the Years 2012, 2018 & 2027

IV. COMPETITION
Total Companies Profiled: 36
Read the full report: https://www.reportlinker.com/p05960378/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
http://news.yahoo.com/



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.